Search
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigationalby the Committee for Medicinal Products for Human Use (CHMP) for a long-term study demonstrating the long-term efficacy and safety of edaravone. … [A19140,L44007,A254257] The intravenous formulation of edaravone was first approved in Japan in 2001 for the treatment of acute ischemic stroke.
Products: RADICAVA™ IV Concentrate Solution for Infusion 30mg/20mLCalfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalCalfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. … Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency.
Products: BLES (bovine lipid extract surfactant) 27 mg/ml Suspension for Intratracheal InstillationOctreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalOn June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. … [L14513] Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).
Products: SANDOSTATIN LAR FOR INJECTION 10 mg, SANDOSTATIN LAR FOR INJECTION 20 mgVoriconazole
go.drugbank.com/drugs/DB00582ApprovedInvestigationalThe increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseProducts: VFEND (200 MG POWDER FOR SOLUTION FOR INFUSION, Voriconazole-AFT 200 mg powder for solution for infusionOseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigational[A180574, L7267, A180580] However, antiviral treatment might be beneficial when initiated after 48 hours for patients with severe, complicated or progressive illness or for hospitalized patients. … Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseProducts: FLUHALT FOR ORAL SUSPENSION 60 mg/ 5 ml, Oseltamivir Phosphate for Oral SuspensionDexrazoxane
go.drugbank.com/drugs/DB00380ApprovedInvestigationalWithdrawn[PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
Categories: Detoxifying Agents for Antineoplastic TreatmentProducts: Dexrazoxane for InjectionPotassium chloride
go.drugbank.com/drugs/DB00761ApprovedInvestigationalWithdrawnThe FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release … dosage forms and those products formulated for preparation of solution prior to ingestion.
Mixtures: Normolyt für Kinder - lösliches Pulver, Prismasol 2 mmol/l Kalium Lösung für Hämofiltration und HämodialyseProducts: Potassium Chloride for Oral Solution, Potassium Chloride for Hemodialysis 7.55Fosaprepitant
go.drugbank.com/drugs/DB06717ApprovedInvestigationalFosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Products: Powder for Solution for Infusion 150mg, Fosaprepitant for InjectionCarbetocin
go.drugbank.com/drugs/DB01282ApprovedInvestigationalCarbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.
Products: DURATOCIN RTS SOLUTION FOR INJECTION 100 MCG/ML, Pharmidea Carbetocin 100 microgram/ml solution for injectionPeginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigational-2a for the treatment of Hepatitis C [A19593]. … When combined together, Peginterferon alfa-2a and [DB00811] have been shown to achieve a SVR between 36% for genotype 1 and 59% for genotypes 2-6 after 48 weeks of treatment.
Categories: Treatments for Hepatitis CProducts: PEGASYS PRE-FILLED SYRINGE FOR INJECTION 180 mcg/0.5 ml, PEGASYS PRE-FILLED SYRINGE FOR INJECTION 135 mcg/0.5 ml